Compare TCRT & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRT | EVGN |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.0M |
| IPO Year | N/A | N/A |
| Metric | TCRT | EVGN |
|---|---|---|
| Price | $3.38 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | ★ 63.3K | 44.7K |
| Earning Date | 11-14-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,000.00 | ★ $8,016,000.00 |
| Revenue This Year | $5,680,500.00 | N/A |
| Revenue Next Year | N/A | $12.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.19 |
| 52 Week Low | $1.31 | $0.95 |
| 52 Week High | $6.20 | $2.42 |
| Indicator | TCRT | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 44.43 |
| Support Level | $3.31 | $0.96 |
| Resistance Level | $4.50 | $1.06 |
| Average True Range (ATR) | 0.37 | 0.05 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 22.83 | 39.10 |
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.